Organization (Industry)
CytoDyn Inc.
ClinicalTrials.gov lists CytoDyn Inc. as lead sponsor of 24 trials. It has 33 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers CytoDyn Inc.: 24 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (10)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| HIV Infections | 7 |
| COVID-19 | 5 |
| Acquired Immunodeficiency Syndrome | 3 |
| Breast Neoplasms | 3 |
| Triple Negative Breast Neoplasms | 3 |
Showing 5 of 10 disease areas.
Trials by start year as sponsor or collaborator (15)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 4 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 2 |
| 2015 | 1 |
| 2014 | 2 |
Showing 10 of 15 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (33)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| PRO 140 | HIV Infections | Phase 2/3 | 5 |
| PRO 140 | Acquired Immunodeficiency Syndrome | Phase 2/3 | 2 |
| 700 mg leronlimab | Colorectal Neoplasms | Phase 2 | 1 |
| 350 mg leronlimab | Colorectal Neoplasms | Phase 2 | 1 |
| 200 mg Pembrolizumab | Colorectal Neoplasms | Phase 2 | 1 |
Showing 5 of 33 active programs.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 50% hit target (n=14) | 23% on time (n=13) |
Journals published in (13)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Medical hypotheses | 2 |
| Alimentary pharmacology & therapeutics | 1 |
| Clinical and experimental immunology | 1 |
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 1 |
| Clinical medicine (London, England) | 1 |
Showing 5 of 13 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 8 | 2 | 2023-02-21 |
SEC-reported annual financials (12)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2026 | not reported | -42,699,000 | not reported |
| 2025 | not reported | 3,745,000 | not reported |
| 2024 | not reported | -49,841,000 | 7,240,000 |
| 2023 | 0 | -79,824,000 | 2,632,000 |
| 2022 | 266,000 | -210,820,000 | 27,043,000 |
| 2021 | 0 | -176,465,000 | 53,403,000 |
| 2020 | not reported | -139,936,000 | 52,640,000 |
| 2019 | not reported | -56,187,000 | 42,490,000 |
| 2018 | not reported | -50,149,681 | 38,222,580 |
| 2017 | not reported | -25,763,801 | 20,205,743 |
Showing 10 of 12 fiscal years.
Financing and grant events (129)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-03-25 | Other financing | not disclosed | Edgar offerings |
| 2026-03-24 | Debt financing | not disclosed | Sec extracted |
| 2026-03-09 | Other financing | not disclosed | Edgar offerings |
| 2026-02-28 | Other financing | not disclosed | Sec extracted |
| 2026-02-27 | Private placement | 18,800,000 | Sec extracted |
Showing 5 of 129 events.
FDA warning letters (1)
| Issue date | Letter |
|---|---|
| 2022-02-11 | cytodyn-inc-626957-02112022 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Amarex Clinical Research, LLC (United States) | Co sponsors trial with | 2 |
| Syneos Health (United States) | Uses vendor | 1 |
| Government of the United States of America | Co sponsors trial with | 1 |
Latest dated events (162)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-25 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-24 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-09 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-02-28 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-02-27 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 162 events.
Biomarker capability evidence (128)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALK | Trial sponsor | Named in trial inclusion criteria |
| CCR5 | Trial sponsor | Named in trial inclusion criteria |
| CCR5 | Trial sponsor | Named in trial inclusion criteria |
| CCR5 | Trial sponsor | Named in trial inclusion criteria |
| CCR5 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 128 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.